Searchable abstracts of presentations at key conferences in endocrinology

ea0083erco6 | Endocrine-related Cancer | EYES2022

Outcome of immuncheckpoint inhibitor therapy in adrenocortical carcinoma – A multicenter retrospective study

H Remde , L Schmidt-Pennington , M Reuter , L Landwehr , M Jensen , H Lahner , K Laubner , J Schreiner , J Bojunga , S Kircher , A Pohrt , M. V. Teleanu , D Hubschmann , A Stenzinger , H Glimm , S Frohling , M Fassnacht , K Mai , M. Kroiss

Background: Adrenocortical carcinoma is a rare endocrine malignancy with poor prognosis and few treatment options in advanced disease. Immune checkpoint inhibitors (ICI) have been studied in few clinical trials with a limited number of patients in ACC. No real-life data are available so far. In the present study we aimed at evaluating treatment response and safety of ICI treatment in advanced ACC and identifying clinical, biochemical, histological and molecular markers for pre...

ea0020p595 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Growth hormone replacement therapy in adult onset growth hormone deficiency induces favorable long-term effects on quality of life, bone, body composition and lipids: a 55 month prospective study

Jorgensen Anders Palmstrom , Fougner Krisitan J , Schreiner Thomas , Bollerslev Jens

Objective: To investigate long-term effects of GH replacement therapy.Material and methods: Thirty-nine patients (mean age 52.5 years, 14 women) with adult-onset growth hormone deficiency (AOGHD), recruited from a randomized placebo-controlled crossover study of treatment with growth hormone (GH) and placebo for 9months each, were enrolled in an open prospective follow up study. GH replacement was given for additional thirty-three months and was individu...